Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,431
archived clinical trials in
Anemia

42-Day Repeat Oral Dose Study of AKB-6548 in Subjects With Chronic Kidney Disease and Anemia
Phase 2a Randomized, Double-Blind, Placebo-Controlled, Dose Range Study to Assess the Pharmacodynamic Response, Pharmacokinetics, Safety, and Tolerability of 42-Day Repeat Oral Doses of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), Stages 3 and 4
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Oklahoma City, OK
42-Day Repeat Oral Dose Study of AKB-6548 in Subjects With Chronic Kidney Disease and Anemia
Phase 2a Randomized, Double-Blind, Placebo-Controlled, Dose Range Study to Assess the Pharmacodynamic Response, Pharmacokinetics, Safety, and Tolerability of 42-Day Repeat Oral Doses of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), Stages 3 and 4
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
42-Day Repeat Oral Dose Study of AKB-6548 in Subjects With Chronic Kidney Disease and Anemia
Phase 2a Randomized, Double-Blind, Placebo-Controlled, Dose Range Study to Assess the Pharmacodynamic Response, Pharmacokinetics, Safety, and Tolerability of 42-Day Repeat Oral Doses of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), Stages 3 and 4
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Knoxville, TN
42-Day Repeat Oral Dose Study of AKB-6548 in Subjects With Chronic Kidney Disease and Anemia
Phase 2a Randomized, Double-Blind, Placebo-Controlled, Dose Range Study to Assess the Pharmacodynamic Response, Pharmacokinetics, Safety, and Tolerability of 42-Day Repeat Oral Doses of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), Stages 3 and 4
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Knoxville, TN
Click here to add this to my saved trials
42-Day Repeat Oral Dose Study of AKB-6548 in Subjects With Chronic Kidney Disease and Anemia
Phase 2a Randomized, Double-Blind, Placebo-Controlled, Dose Range Study to Assess the Pharmacodynamic Response, Pharmacokinetics, Safety, and Tolerability of 42-Day Repeat Oral Doses of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), Stages 3 and 4
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Austin, TX
42-Day Repeat Oral Dose Study of AKB-6548 in Subjects With Chronic Kidney Disease and Anemia
Phase 2a Randomized, Double-Blind, Placebo-Controlled, Dose Range Study to Assess the Pharmacodynamic Response, Pharmacokinetics, Safety, and Tolerability of 42-Day Repeat Oral Doses of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), Stages 3 and 4
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Austin, TX
Click here to add this to my saved trials
42-Day Repeat Oral Dose Study of AKB-6548 in Subjects With Chronic Kidney Disease and Anemia
Phase 2a Randomized, Double-Blind, Placebo-Controlled, Dose Range Study to Assess the Pharmacodynamic Response, Pharmacokinetics, Safety, and Tolerability of 42-Day Repeat Oral Doses of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), Stages 3 and 4
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Fort Worth, TX
42-Day Repeat Oral Dose Study of AKB-6548 in Subjects With Chronic Kidney Disease and Anemia
Phase 2a Randomized, Double-Blind, Placebo-Controlled, Dose Range Study to Assess the Pharmacodynamic Response, Pharmacokinetics, Safety, and Tolerability of 42-Day Repeat Oral Doses of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), Stages 3 and 4
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Fort Worth, TX
Click here to add this to my saved trials
42-Day Repeat Oral Dose Study of AKB-6548 in Subjects With Chronic Kidney Disease and Anemia
Phase 2a Randomized, Double-Blind, Placebo-Controlled, Dose Range Study to Assess the Pharmacodynamic Response, Pharmacokinetics, Safety, and Tolerability of 42-Day Repeat Oral Doses of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), Stages 3 and 4
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Houston, TX
42-Day Repeat Oral Dose Study of AKB-6548 in Subjects With Chronic Kidney Disease and Anemia
Phase 2a Randomized, Double-Blind, Placebo-Controlled, Dose Range Study to Assess the Pharmacodynamic Response, Pharmacokinetics, Safety, and Tolerability of 42-Day Repeat Oral Doses of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), Stages 3 and 4
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
42-Day Repeat Oral Dose Study of AKB-6548 in Subjects With Chronic Kidney Disease and Anemia
Phase 2a Randomized, Double-Blind, Placebo-Controlled, Dose Range Study to Assess the Pharmacodynamic Response, Pharmacokinetics, Safety, and Tolerability of 42-Day Repeat Oral Doses of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), Stages 3 and 4
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
San Antonio, TX
42-Day Repeat Oral Dose Study of AKB-6548 in Subjects With Chronic Kidney Disease and Anemia
Phase 2a Randomized, Double-Blind, Placebo-Controlled, Dose Range Study to Assess the Pharmacodynamic Response, Pharmacokinetics, Safety, and Tolerability of 42-Day Repeat Oral Doses of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), Stages 3 and 4
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
Study Comparing Blood Levels of ReFacto and Advante in Hemophilia A
A Single Dose, Randomized, 2-Period Crossover Study in Patients With Hemophilia A to Evaluate the Pharmacokinetics of ReFacto (B-domain Deleted Recombinant Human Factor VIII (BDDrFVIII) and Advante (a Full-length Recombinant Factor VIII (FLrFVIII)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Washington,
Study Comparing Blood Levels of ReFacto and Advante in Hemophilia A
A Single Dose, Randomized, 2-Period Crossover Study in Patients With Hemophilia A to Evaluate the Pharmacokinetics of ReFacto (B-domain Deleted Recombinant Human Factor VIII (BDDrFVIII) and Advante (a Full-length Recombinant Factor VIII (FLrFVIII)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Washington,
Click here to add this to my saved trials
Study Comparing Blood Levels of ReFacto and Advante in Hemophilia A
A Single Dose, Randomized, 2-Period Crossover Study in Patients With Hemophilia A to Evaluate the Pharmacokinetics of ReFacto (B-domain Deleted Recombinant Human Factor VIII (BDDrFVIII) and Advante (a Full-length Recombinant Factor VIII (FLrFVIII)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Atlanta, GA
Study Comparing Blood Levels of ReFacto and Advante in Hemophilia A
A Single Dose, Randomized, 2-Period Crossover Study in Patients With Hemophilia A to Evaluate the Pharmacokinetics of ReFacto (B-domain Deleted Recombinant Human Factor VIII (BDDrFVIII) and Advante (a Full-length Recombinant Factor VIII (FLrFVIII)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
Study Comparing Blood Levels of ReFacto and Advante in Hemophilia A
A Single Dose, Randomized, 2-Period Crossover Study in Patients With Hemophilia A to Evaluate the Pharmacokinetics of ReFacto (B-domain Deleted Recombinant Human Factor VIII (BDDrFVIII) and Advante (a Full-length Recombinant Factor VIII (FLrFVIII)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Iowa City, IA
Study Comparing Blood Levels of ReFacto and Advante in Hemophilia A
A Single Dose, Randomized, 2-Period Crossover Study in Patients With Hemophilia A to Evaluate the Pharmacokinetics of ReFacto (B-domain Deleted Recombinant Human Factor VIII (BDDrFVIII) and Advante (a Full-length Recombinant Factor VIII (FLrFVIII)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Iowa City, IA
Click here to add this to my saved trials
Study Comparing Blood Levels of ReFacto and Advante in Hemophilia A
A Single Dose, Randomized, 2-Period Crossover Study in Patients With Hemophilia A to Evaluate the Pharmacokinetics of ReFacto (B-domain Deleted Recombinant Human Factor VIII (BDDrFVIII) and Advante (a Full-length Recombinant Factor VIII (FLrFVIII)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
New Orleans, LA
Study Comparing Blood Levels of ReFacto and Advante in Hemophilia A
A Single Dose, Randomized, 2-Period Crossover Study in Patients With Hemophilia A to Evaluate the Pharmacokinetics of ReFacto (B-domain Deleted Recombinant Human Factor VIII (BDDrFVIII) and Advante (a Full-length Recombinant Factor VIII (FLrFVIII)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
New Orleans, LA
Click here to add this to my saved trials
Study Comparing Blood Levels of ReFacto and Advante in Hemophilia A
A Single Dose, Randomized, 2-Period Crossover Study in Patients With Hemophilia A to Evaluate the Pharmacokinetics of ReFacto (B-domain Deleted Recombinant Human Factor VIII (BDDrFVIII) and Advante (a Full-length Recombinant Factor VIII (FLrFVIII)
Status: Enrolling
Updated:  12/31/1969
Investigational Site
mi
from
Brussels,
Study Comparing Blood Levels of ReFacto and Advante in Hemophilia A
A Single Dose, Randomized, 2-Period Crossover Study in Patients With Hemophilia A to Evaluate the Pharmacokinetics of ReFacto (B-domain Deleted Recombinant Human Factor VIII (BDDrFVIII) and Advante (a Full-length Recombinant Factor VIII (FLrFVIII)
Status: Enrolling
Updated: 12/31/1969
Investigational Site
mi
from
Brussels,
Click here to add this to my saved trials
Transfusions and Nitric Oxide Level in Preterm Infants
Transfusions and Nitric Oxide Level in Preterm Infants
Status: Enrolling
Updated:  12/31/1969
Duke Univ Med Ctr
mi
from
Durham, NC
Transfusions and Nitric Oxide Level in Preterm Infants
Transfusions and Nitric Oxide Level in Preterm Infants
Status: Enrolling
Updated: 12/31/1969
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
BEATS 2: Music Therapy in Sickle Cell
BEATS 2: The Effects of Music Therapy on Young Adults With Sickle Cell Disease
Status: Enrolling
Updated:  12/31/1969
University Hospitals Seidman Cancer Center
mi
from
Cleveland, OH
BEATS 2: Music Therapy in Sickle Cell
BEATS 2: The Effects of Music Therapy on Young Adults With Sickle Cell Disease
Status: Enrolling
Updated: 12/31/1969
University Hospitals Seidman Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Blood Transplantation for Patients With Hematologic Malignancies or Bone Marrow Failure States
Megadose T-cell Depleted HLA-nonidentical Blood Progenitor Cell Transplantation for Patients With Hematologic Malignancies or Bone Marrow Failure States
Status: Enrolling
Updated:  12/31/1969
M.D. Anderson Cancer Center
mi
from
Houston, TX
Blood Transplantation for Patients With Hematologic Malignancies or Bone Marrow Failure States
Megadose T-cell Depleted HLA-nonidentical Blood Progenitor Cell Transplantation for Patients With Hematologic Malignancies or Bone Marrow Failure States
Status: Enrolling
Updated: 12/31/1969
M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
How Does a Synbiotic Supplement Affect Iron Status During Iron Repletion in Iron Depleted Female Athletes?
How Does a Synbiotic Supplement Affect Iron Status During Iron Repletion in Iron Depleted Female Athletes?
Status: Enrolling
Updated:  12/31/1969
Marywood University
mi
from
Scranton, PA
How Does a Synbiotic Supplement Affect Iron Status During Iron Repletion in Iron Depleted Female Athletes?
How Does a Synbiotic Supplement Affect Iron Status During Iron Repletion in Iron Depleted Female Athletes?
Status: Enrolling
Updated: 12/31/1969
Marywood University
mi
from
Scranton, PA
Click here to add this to my saved trials
Study of High Dose Cyclophosphamide in Patients With Severe Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria
High Dose Cyclophosphamide for the Treatment of Severe Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria
Status: Enrolling
Updated:  12/31/1969
Johns Hopkins Oncology Center
mi
from
Baltimore, MD
Study of High Dose Cyclophosphamide in Patients With Severe Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria
High Dose Cyclophosphamide for the Treatment of Severe Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins Oncology Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Red Blood Cell Transfusion in the Ambulatory Setting: Impact on Home Functional Status
Red Blood Cell Transfusion in the Ambulatory Setting: Impact on Home Functional Status
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Red Blood Cell Transfusion in the Ambulatory Setting: Impact on Home Functional Status
Red Blood Cell Transfusion in the Ambulatory Setting: Impact on Home Functional Status
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Iron Deficiency and FGF23 Regulation in CKD and HF
Iron Deficiency and Fibroblast Growth Factor 23 Regulation in Chronic Kidney Disease and Heart Failure
Status: Enrolling
Updated:  12/31/1969
Northwestern University
mi
from
Chicago, IL
Iron Deficiency and FGF23 Regulation in CKD and HF
Iron Deficiency and Fibroblast Growth Factor 23 Regulation in Chronic Kidney Disease and Heart Failure
Status: Enrolling
Updated: 12/31/1969
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Spot-Check Noninvasive Hemoglobin (SpHb) Clinical Validation
Spot-Check Noninvasive Hemoglobin (SpHb) Clinical Validation
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Burbank, CA
Spot-Check Noninvasive Hemoglobin (SpHb) Clinical Validation
Spot-Check Noninvasive Hemoglobin (SpHb) Clinical Validation
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Burbank, CA
Click here to add this to my saved trials
Spot-Check Noninvasive Hemoglobin (SpHb) Clinical Validation
Spot-Check Noninvasive Hemoglobin (SpHb) Clinical Validation
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Irvine, CA
Spot-Check Noninvasive Hemoglobin (SpHb) Clinical Validation
Spot-Check Noninvasive Hemoglobin (SpHb) Clinical Validation
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Irvine, CA
Click here to add this to my saved trials
Spot-Check Noninvasive Hemoglobin (SpHb) Clinical Validation
Spot-Check Noninvasive Hemoglobin (SpHb) Clinical Validation
Status: Enrolling
Updated:  12/31/1969
Research Site
mi
from
Lake Forest, CA
Spot-Check Noninvasive Hemoglobin (SpHb) Clinical Validation
Spot-Check Noninvasive Hemoglobin (SpHb) Clinical Validation
Status: Enrolling
Updated: 12/31/1969
Research Site
mi
from
Lake Forest, CA
Click here to add this to my saved trials
Spot-Check Noninvasive Hemoglobin (SpHb) Clinical Validation
Spot-Check Noninvasive Hemoglobin (SpHb) Clinical Validation
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
National City, CA
Spot-Check Noninvasive Hemoglobin (SpHb) Clinical Validation
Spot-Check Noninvasive Hemoglobin (SpHb) Clinical Validation
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
National City, CA
Click here to add this to my saved trials
Spot-Check Noninvasive Hemoglobin (SpHb) Clinical Validation
Spot-Check Noninvasive Hemoglobin (SpHb) Clinical Validation
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Torrance, CA
Spot-Check Noninvasive Hemoglobin (SpHb) Clinical Validation
Spot-Check Noninvasive Hemoglobin (SpHb) Clinical Validation
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Torrance, CA
Click here to add this to my saved trials
Spot-Check Noninvasive Hemoglobin (SpHb) Clinical Validation
Spot-Check Noninvasive Hemoglobin (SpHb) Clinical Validation
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Charlotte, NC
Spot-Check Noninvasive Hemoglobin (SpHb) Clinical Validation
Spot-Check Noninvasive Hemoglobin (SpHb) Clinical Validation
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Charlotte, NC
Click here to add this to my saved trials
Spot-Check Noninvasive Hemoglobin (SpHb) Repeatability and Reproducibility
Spot-Check Noninvasive Hemoglobin (SpHb) Repeatability and Reproducibility
Status: Enrolling
Updated:  12/31/1969
Masimo Clinical Laboratory
mi
from
Irvine, CA
Spot-Check Noninvasive Hemoglobin (SpHb) Repeatability and Reproducibility
Spot-Check Noninvasive Hemoglobin (SpHb) Repeatability and Reproducibility
Status: Enrolling
Updated: 12/31/1969
Masimo Clinical Laboratory
mi
from
Irvine, CA
Click here to add this to my saved trials
Spot-Check Noninvasive Hemoglobin (SpHb) Repeatability and Reproducibility
Spot-Check Noninvasive Hemoglobin (SpHb) Repeatability and Reproducibility
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Charlotte, NC
Spot-Check Noninvasive Hemoglobin (SpHb) Repeatability and Reproducibility
Spot-Check Noninvasive Hemoglobin (SpHb) Repeatability and Reproducibility
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Charlotte, NC
Click here to add this to my saved trials
Spot-Check Noninvasive Hemoglobin (SpHb) Clinical Validation of INVSENSOR00026
Spot-Check Noninvasive Hemoglobin (SpHb) Clinical Validation of INVSENSOR00026
Status: Enrolling
Updated:  12/31/1969
Torrance Clinical Research
mi
from
Lomita, CA
Spot-Check Noninvasive Hemoglobin (SpHb) Clinical Validation of INVSENSOR00026
Spot-Check Noninvasive Hemoglobin (SpHb) Clinical Validation of INVSENSOR00026
Status: Enrolling
Updated: 12/31/1969
Torrance Clinical Research
mi
from
Lomita, CA
Click here to add this to my saved trials
Arginine Treatment of Acute Chest Syndrome (Pneumonia) in Sickle Cell Disease Patients
Arginine Therapy for Acute Chest Syndrome in Sickle Cell Disease
Status: Enrolling
Updated:  6/23/2005
Children's Hospital Oakland
mi
from
Oakland, CA
Arginine Treatment of Acute Chest Syndrome (Pneumonia) in Sickle Cell Disease Patients
Arginine Therapy for Acute Chest Syndrome in Sickle Cell Disease
Status: Enrolling
Updated: 6/23/2005
Children's Hospital Oakland
mi
from
Oakland, CA
Click here to add this to my saved trials
Safety and Tolerability of Intravenous VIT-45 in Patients With Iron Deficiency Anemia
A Multi-Center, Randomized, Blinded, Placebo Controlled, Cross-Over Study to Investigate the Safety and Tolerability of Intravenous VIT-45 in Patients With Iron Deficiency Anemia
Status: Enrolling
Updated:  8/21/2008
Luitpold Pharmaceuticals, Inc.
mi
from
Norristown, PA
Safety and Tolerability of Intravenous VIT-45 in Patients With Iron Deficiency Anemia
A Multi-Center, Randomized, Blinded, Placebo Controlled, Cross-Over Study to Investigate the Safety and Tolerability of Intravenous VIT-45 in Patients With Iron Deficiency Anemia
Status: Enrolling
Updated: 8/21/2008
Luitpold Pharmaceuticals, Inc.
mi
from
Norristown, PA
Click here to add this to my saved trials
Sirolimus and Cyclosporine for Treatment-Resistant Aplastic Anemia
A Phase I/II Trial of Sirolimus (Rapamune) and Cyclosporine in Patients With Refractory Aplastic Anemia
Status: Enrolling
Updated:  10/6/2008
UCLA Center for Health Sciences
mi
from
Los Angeles, CA
Sirolimus and Cyclosporine for Treatment-Resistant Aplastic Anemia
A Phase I/II Trial of Sirolimus (Rapamune) and Cyclosporine in Patients With Refractory Aplastic Anemia
Status: Enrolling
Updated: 10/6/2008
UCLA Center for Health Sciences
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Sirolimus and Cyclosporine for Treatment-Resistant Aplastic Anemia
A Phase I/II Trial of Sirolimus (Rapamune) and Cyclosporine in Patients With Refractory Aplastic Anemia
Status: Enrolling
Updated:  10/6/2008
Lee Moffitt Cancer Center
mi
from
Tampa, FL
Sirolimus and Cyclosporine for Treatment-Resistant Aplastic Anemia
A Phase I/II Trial of Sirolimus (Rapamune) and Cyclosporine in Patients With Refractory Aplastic Anemia
Status: Enrolling
Updated: 10/6/2008
Lee Moffitt Cancer Center
mi
from
Tampa, FL
Click here to add this to my saved trials
Sirolimus and Cyclosporine for Treatment-Resistant Aplastic Anemia
A Phase I/II Trial of Sirolimus (Rapamune) and Cyclosporine in Patients With Refractory Aplastic Anemia
Status: Enrolling
Updated:  10/6/2008
Taussig Cancer Center, Cleveland Clinic Foundation
mi
from
Cleveland, OH
Sirolimus and Cyclosporine for Treatment-Resistant Aplastic Anemia
A Phase I/II Trial of Sirolimus (Rapamune) and Cyclosporine in Patients With Refractory Aplastic Anemia
Status: Enrolling
Updated: 10/6/2008
Taussig Cancer Center, Cleveland Clinic Foundation
mi
from
Cleveland, OH
Click here to add this to my saved trials
Sirolimus and Cyclosporine for Treatment-Resistant Aplastic Anemia
A Phase I/II Trial of Sirolimus (Rapamune) and Cyclosporine in Patients With Refractory Aplastic Anemia
Status: Enrolling
Updated:  10/6/2008
Penn State University Cancer Center
mi
from
Hershey, PA
Sirolimus and Cyclosporine for Treatment-Resistant Aplastic Anemia
A Phase I/II Trial of Sirolimus (Rapamune) and Cyclosporine in Patients With Refractory Aplastic Anemia
Status: Enrolling
Updated: 10/6/2008
Penn State University Cancer Center
mi
from
Hershey, PA
Click here to add this to my saved trials
A Pilot Study of HSCT for Patients With High-Risk Hemoglobinopathy Using a Nonmyeloablative Preparative Regimen
A Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With High Risk Hemoglobinopathy Using a Non-Myeloablative Preparative Regimen to Achieve Stable Mixed Chimerism
Status: Enrolling
Updated:  10/16/2008
Children's Hospital of Pittsburgh
mi
from
Pittsburgh, PA
A Pilot Study of HSCT for Patients With High-Risk Hemoglobinopathy Using a Nonmyeloablative Preparative Regimen
A Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With High Risk Hemoglobinopathy Using a Non-Myeloablative Preparative Regimen to Achieve Stable Mixed Chimerism
Status: Enrolling
Updated: 10/16/2008
Children's Hospital of Pittsburgh
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Helicobacter Pylori Eradication Trial to Reduce Iron Deficiency in Children
Randomized Field Intervention Trial of H. Pylori Eradication to Reduce Iron Deficiency Among Children in El Paso, Texas
Status: Enrolling
Updated:  6/26/2009
Texas Tech University School of Medicine
mi
from
El Paso, TX
Helicobacter Pylori Eradication Trial to Reduce Iron Deficiency in Children
Randomized Field Intervention Trial of H. Pylori Eradication to Reduce Iron Deficiency Among Children in El Paso, Texas
Status: Enrolling
Updated: 6/26/2009
Texas Tech University School of Medicine
mi
from
El Paso, TX
Click here to add this to my saved trials
Effectiveness of a Computerized Tool (PAINRelieveIt) to Help Manage Pain Related to Sickle Cell Disease
Computerized PAINRelieveIt for Adult Sickle Cell Disease
Status: Enrolling
Updated:  7/24/2009
University of Illinois at Chicago Sickle Cell Center and Medical Center
mi
from
Chicago, IL
Effectiveness of a Computerized Tool (PAINRelieveIt) to Help Manage Pain Related to Sickle Cell Disease
Computerized PAINRelieveIt for Adult Sickle Cell Disease
Status: Enrolling
Updated: 7/24/2009
University of Illinois at Chicago Sickle Cell Center and Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
SALT: Alternative Donor Bone Marrow and Cord Blood Transplantation for High Risk Sickle Cell Disease
SALT - Alternative Donor Bone Marrow and Cord Blood Transplantation for High Risk Sickle Cell Disease
Status: Enrolling
Updated:  8/27/2009
Children's Healthcare of Altanta
mi
from
Atlanta, GA
SALT: Alternative Donor Bone Marrow and Cord Blood Transplantation for High Risk Sickle Cell Disease
SALT - Alternative Donor Bone Marrow and Cord Blood Transplantation for High Risk Sickle Cell Disease
Status: Enrolling
Updated: 8/27/2009
Children's Healthcare of Altanta
mi
from
Atlanta, GA
Click here to add this to my saved trials
Clinical Importance of Treating Iron Overload in Sickle Cell Disease
Clinical Importance of Treating Iron Overload in Sickle Cell Disease
Status: Enrolling
Updated:  9/21/2009
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Clinical Importance of Treating Iron Overload in Sickle Cell Disease
Clinical Importance of Treating Iron Overload in Sickle Cell Disease
Status: Enrolling
Updated: 9/21/2009
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Clinical Importance of Treating Iron Overload in Sickle Cell Disease
Clinical Importance of Treating Iron Overload in Sickle Cell Disease
Status: Enrolling
Updated:  9/21/2009
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Clinical Importance of Treating Iron Overload in Sickle Cell Disease
Clinical Importance of Treating Iron Overload in Sickle Cell Disease
Status: Enrolling
Updated: 9/21/2009
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Kidney Transplantation in Patients With Sickle Cell Disease
Kidney Transplantation in Patients With Sickle Cell Disease
Status: Enrolling
Updated:  5/25/2010
Mason Outpatient Tranplant Clinic Emory University
mi
from
Atlanta, GA
Kidney Transplantation in Patients With Sickle Cell Disease
Kidney Transplantation in Patients With Sickle Cell Disease
Status: Enrolling
Updated: 5/25/2010
Mason Outpatient Tranplant Clinic Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Study of Propranolol as Anti-Adhesive Therapy in Sickle Cell Disease (SCD)
Phase II Study of Propranolol as Anti-Adhesive Therapy for Sickle Cell Disease
Status: Enrolling
Updated:  10/7/2010
Duke Univ Med Ctr
mi
from
Durham, NC
Study of Propranolol as Anti-Adhesive Therapy in Sickle Cell Disease (SCD)
Phase II Study of Propranolol as Anti-Adhesive Therapy for Sickle Cell Disease
Status: Enrolling
Updated: 10/7/2010
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
A Randomized Trial of LOVAZA in Pediatric Sickle Cell Disease (SCD)
Phase II Randomized Double-Blind Placebo-Controlled Trial of the Omega-3 Fatty Acids Eicosapentaenoic (EPA) and Docosahexaenoic Acid (DHA) in Pediatric Sickle Cell Disease (SCD)
Status: Enrolling
Updated:  10/22/2010
Thomas Jefferson University Hospital
mi
from
Philadelphia, PA
A Randomized Trial of LOVAZA in Pediatric Sickle Cell Disease (SCD)
Phase II Randomized Double-Blind Placebo-Controlled Trial of the Omega-3 Fatty Acids Eicosapentaenoic (EPA) and Docosahexaenoic Acid (DHA) in Pediatric Sickle Cell Disease (SCD)
Status: Enrolling
Updated: 10/22/2010
Thomas Jefferson University Hospital
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Randomized Trial of LOVAZA in Pediatric Sickle Cell Disease (SCD)
Phase II Randomized Double-Blind Placebo-Controlled Trial of the Omega-3 Fatty Acids Eicosapentaenoic (EPA) and Docosahexaenoic Acid (DHA) in Pediatric Sickle Cell Disease (SCD)
Status: Enrolling
Updated:  10/22/2010
St. Christopher's Hospital for Children, Drexel University
mi
from
Philadelphia, PA
A Randomized Trial of LOVAZA in Pediatric Sickle Cell Disease (SCD)
Phase II Randomized Double-Blind Placebo-Controlled Trial of the Omega-3 Fatty Acids Eicosapentaenoic (EPA) and Docosahexaenoic Acid (DHA) in Pediatric Sickle Cell Disease (SCD)
Status: Enrolling
Updated: 10/22/2010
St. Christopher's Hospital for Children, Drexel University
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Females With Severe or Moderate Hemophilia A or B: an International Multi-center Study
Females With Severe or Moderate Hemophilia A or B: an International Multi-center Study
Status: Enrolling
Updated:  11/17/2010
New York Presbyterian Hospital
mi
from
White Plains, NY
Females With Severe or Moderate Hemophilia A or B: an International Multi-center Study
Females With Severe or Moderate Hemophilia A or B: an International Multi-center Study
Status: Enrolling
Updated: 11/17/2010
New York Presbyterian Hospital
mi
from
White Plains, NY
Click here to add this to my saved trials
Steroid Treatment for Sickle Cell Pain Crisis
Randomized Trial of High-dose Intravenous Methylprednisolone and Steroid Taper for Vaso-occlusive Crises in Sickle Cell Disease
Status: Enrolling
Updated:  11/30/2010
Texas Children's Hospital
mi
from
Houston, TX
Steroid Treatment for Sickle Cell Pain Crisis
Randomized Trial of High-dose Intravenous Methylprednisolone and Steroid Taper for Vaso-occlusive Crises in Sickle Cell Disease
Status: Enrolling
Updated: 11/30/2010
Texas Children's Hospital
mi
from
Houston, TX
Click here to add this to my saved trials
Delayed Cord Clamping in Premature Infants
Delayed Cord Clamping: Prevention of Anemia and Hypothermia in Premature Infants
Status: Enrolling
Updated:  3/14/2011
UC Davis Medical Center
mi
from
Sacramento, CA
Delayed Cord Clamping in Premature Infants
Delayed Cord Clamping: Prevention of Anemia and Hypothermia in Premature Infants
Status: Enrolling
Updated: 3/14/2011
UC Davis Medical Center
mi
from
Sacramento, CA
Click here to add this to my saved trials
Pilot Lenalidomide in Adult Diamond-Blackfan Anemia Patients w/ RBC Transfusion-Dependent Anemia
A Pilot Study of Lenalidomide in Adult Diamond-Blackfan Anemia Patients With Red Blood Cell Transfusion-Dependent Anemia
Status: Enrolling
Updated:  3/21/2011
Stanford University School of Medicine
mi
from
Stanford, CA
Pilot Lenalidomide in Adult Diamond-Blackfan Anemia Patients w/ RBC Transfusion-Dependent Anemia
A Pilot Study of Lenalidomide in Adult Diamond-Blackfan Anemia Patients With Red Blood Cell Transfusion-Dependent Anemia
Status: Enrolling
Updated: 3/21/2011
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
Topical Tranexamic Acid and Acute Blood Loss in Total Knee Arthroplasty
Topical Tranexamic Acid and Acute Blood Loss in Total Knee Arthroplasty
Status: Enrolling
Updated:  6/8/2011
Henry Ford Hospital
mi
from
Detroit, MI
Topical Tranexamic Acid and Acute Blood Loss in Total Knee Arthroplasty
Topical Tranexamic Acid and Acute Blood Loss in Total Knee Arthroplasty
Status: Enrolling
Updated: 6/8/2011
Henry Ford Hospital
mi
from
Detroit, MI
Click here to add this to my saved trials
Ranibizumab for Neovascularization in Sickle Cell Retinopathy
A Phase I Study to Evaluate the Ocular and Non Ocular Safety of Ranibizumab in Treating Neovascularization Secondary to Sickle Cell Retinopathy
Status: Enrolling
Updated:  6/21/2011
Kresge Eye Institute
mi
from
Detroit, MI
Ranibizumab for Neovascularization in Sickle Cell Retinopathy
A Phase I Study to Evaluate the Ocular and Non Ocular Safety of Ranibizumab in Treating Neovascularization Secondary to Sickle Cell Retinopathy
Status: Enrolling
Updated: 6/21/2011
Kresge Eye Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
Inhaled Nitric Oxide for Pediatric Painful Sickle Crisis
Inhaled Nitric Oxide for Pediatric Painful Sickle Crisis
Status: Enrolling
Updated:  7/15/2011
Children's Hospital - Boston
mi
from
Boston, MA
Inhaled Nitric Oxide for Pediatric Painful Sickle Crisis
Inhaled Nitric Oxide for Pediatric Painful Sickle Crisis
Status: Enrolling
Updated: 7/15/2011
Children's Hospital - Boston
mi
from
Boston, MA
Click here to add this to my saved trials